This article is part of a Chronicle. See more from this Chronicle
Kalyani Singh, Nov 24, 2014
Given the sensitivity and direct impact on consumers, it is of little surprise that the pharmaceutical industry—if not an absolute—ranks as one of the most controversial and actively pursued sectors by antitrust authorities across the world. India is no exception to this rule.
On September 4, 2014, the Competition Commission of India (“CCI”) issued a notice seeking public comments subsequent to
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.119.107.96
Please verify email or join us to access premium content!